㈱レグイミューン
4 known investors
RegImmune develops immune-modulation therapies that use regulatory T cells to induce immune tolerance or to trigger anti-tumor immune responses. Its pipeline includes treatments targeting conditions such as graft-versus-host disease (GvHD).
Investors · 4
Frequently asked questions
- What does ㈱レグイミューン do?
- RegImmune develops immune-modulation therapies that use regulatory T cells to induce immune tolerance or to trigger anti-tumor immune responses. Its pipeline includes treatments targeting conditions such as graft-versus-host disease (GvHD).
- Who are ㈱レグイミューン's investors?
- ㈱レグイミューン's investors include DBJ Capital, Hiroshima Venture Capital Co. Ltd., Miyako Capital, Oita Venture Capital.